Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LQDA 
Liquidia Technologies Inc (LQDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LQDA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 3.98% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.24B USD | Price to earnings Ratio - | 1Y Target Price 26.78 |
Price to earnings Ratio - | 1Y Target Price 26.78 | ||
Volume (30-day avg) 918821 | Beta 0.07 | 52 Weeks Range 8.26 - 16.81 | Updated Date 04/1/2025 |
52 Weeks Range 8.26 - 16.81 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate -0.395 | Actual -0.45 |
Profitability
Profit Margin - | Operating Margin (TTM) -1237.81% |
Management Effectiveness
Return on Assets (TTM) -43.49% | Return on Equity (TTM) -209.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1183592832 | Price to Sales(TTM) 92.03 |
Enterprise Value 1183592832 | Price to Sales(TTM) 92.03 | ||
Enterprise Value to Revenue 88.1 | Enterprise Value to EBITDA -9.43 | Shares Outstanding 85298496 | Shares Floating 66209577 |
Shares Outstanding 85298496 | Shares Floating 66209577 | ||
Percent Insiders 13.77 | Percent Institutions 60.92 |
Analyst Ratings
Rating 4.55 | Target Price 25.3 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Liquidia Technologies Inc
Company Overview
History and Background
Liquidia Technologies Inc. was founded in 2004. It's a biopharmaceutical company focused on developing, manufacturing and commercializing products that address unmet needs in pulmonary hypertension and other diseases.
Core Business Areas
- LIQ861 (Yutrepiau2122): Yutrepia is an inhaled dry powder formulation of treprostinil. It is approved in the U.S. for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. It leverages Liquidiau2019s PRINTu00ae technology.
- PRINTu00ae Technology: Liquidia's proprietary PRINTu00ae (Particle Replication In Non-Wetting Templates) technology allows for the precise design and manufacturing of uniform drug particles. This enables the creation of differentiated inhaled therapies.
Leadership and Structure
The leadership team consists of senior executives with experience in pharmaceutical development, manufacturing, and commercialization. Organizational structure is typical of a biopharmaceutical company, including research, development, manufacturing, and commercial functions. Damien de Chillaz is the CEO.
Top Products and Market Share
Key Offerings
- Yutrepiau2122 (Treprostinil Inhalation Powder): Indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. As a newly approved product, precise market share data is still developing. Competitors include United Therapeutics (UTHR) with Remodulin and Tyvaso.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the pulmonary hypertension market, is characterized by significant unmet needs and high drug prices. It's a competitive landscape with both established players and emerging companies.
Positioning
Liquidia is positioning itself as an innovator in inhaled therapies through its PRINTu00ae technology. It aims to offer differentiated products with improved efficacy and patient convenience. They have a competitive advantage in pulmonary delivery due to the PRINT technology.
Total Addressable Market (TAM)
The global pulmonary hypertension market is projected to reach approximately $7 billion. Liquidia, with Yutrepia, aims to capture a significant portion of this market with its differentiated inhaled therapy.
Upturn SWOT Analysis
Strengths
- Proprietary PRINTu00ae technology platform
- FDA approved drug Yutrepia
- Experienced management team
- Targeted approach to pulmonary hypertension
Weaknesses
- Limited commercial infrastructure
- Reliance on single product (Yutrepia) for revenue
- Need for additional funding for commercialization and R&D
- Competition from established players
Opportunities
- Expanding Yutrepia market share
- Developing new products based on PRINTu00ae technology
- Partnerships and collaborations with larger pharmaceutical companies
- Expanding into new therapeutic areas
Threats
- Competition from existing therapies
- Regulatory hurdles
- Patent challenges
- Commercialization risks
Competitors and Market Share
Key Competitors
- UTHR
- ALNY
- MRTX
Competitive Landscape
Liquidia's PRINTu00ae technology offers a competitive advantage, but the company faces competition from larger, established players with greater resources and broader product portfolios. Liquidia is significantly smaller and lacks commercial infrastructure in comparison.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by R&D and clinical trial progress.
Future Projections: Future growth is projected to be driven by the successful commercialization of Yutrepia and the development of new products.
Recent Initiatives: Recent initiatives include the commercial launch of Yutrepia, efforts to secure reimbursement coverage, and ongoing R&D programs.
Summary
Liquidia is a biopharmaceutical company with a focus on pulmonary hypertension. Its PRINT technology provides a competitive edge. The company's success is primarily dependent on the success of Yutrepia's commercialization. It needs to grow its commercial infrastructure, secure reimbursement, and manage cash flow effectively.
Similar Companies
- UTHR
- ALNY
- MRTX
Sources and Disclaimers
Data Sources:
- Liquidia Technologies Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. This information is based on available data and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liquidia Technologies Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 2018-07-26 | CEO & Director Dr. Roger A. Jeffs Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 170 | Website https://www.liquidia.com |
Full time employees 170 | Website https://www.liquidia.com | ||
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.